Literature DB >> 11953366

Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Kei Amemiya1, Gary V Bush, David DeShazer, David M Waag.   

Abstract

Nonviable cell preparations of Burkholderia mallei, the causative agent of glanders, were evaluated as potential vaccine candidates in a BALB/c murine model. Three different B. mallei cell preparations plus Alhydrogel were evaluated: a heat-killed preparation, an irradiation-inactivated preparation, and a preparation of a capsule-negative mutant strain which had been irradiation inactivated. BALB/c mice were vaccinated twice with the different B. mallei preparations, and spleens and sera were collected to determine their cellular and humoral immune responses. All three bacterial cell preparations had essentially the same results in two cellular immune response assays. In a splenocyte proliferation assay, the amount of cell proliferation in response to the homologous immunogen, concanavalin A, or lipopolysaccharide was similar for all the cell preparations. Also, splenocytes from the inoculated mice expressed interleukin 2 (IL-2), gamma interferon, and small amounts of IL-4 and IL-5, and more IL-10 cytokine in the presence of the homologous antigen. When the immunoglobulin subclasses from these mice were examined, they all produced higher levels of IgG1 than IgG2a subclasses. The higher ratio of IgG1 to IgG2a was not due to the amount of the immunogen or the adjuvant (Alhydrogel) used in the BALB/c mice. The cell preparations did not protect the vaccinated mice from a live challenge (>300 50% lethal doses). Our results suggest that in BALB/c mice, a mixed T-helper-cell-like response to nonviable B. mallei is obtained, as demonstrated by a Th1- and Th2-like cytokine response and a Th2-like subclass immunoglobulin response. This may be the reason for the inability of the B. mallei cells that were examined as candidate vaccines to protect the mice from a live challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953366      PMCID: PMC127890          DOI: 10.1128/IAI.70.5.2319-2325.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-04-21

Review 2.  Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm.

Authors:  D R Lucey
Journal:  Infect Dis Clin North Am       Date:  1999-03       Impact factor: 5.982

3.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Authors:  D Jankovic; P Caspar; M Zweig; M Garcia-Moll; S D Showalter; F R Vogel; A Sher
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

4.  Human glanders; report of six cases.

Authors:  C HOWE; W R MILLER
Journal:  Ann Intern Med       Date:  1947-01       Impact factor: 25.391

5.  Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant.

Authors:  D DeShazer; D M Waag; D L Fritz; D E Woods
Journal:  Microb Pathog       Date:  2001-05       Impact factor: 3.738

6.  Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species.

Authors:  P J Brett; D DeShazer; D E Woods
Journal:  Int J Syst Bacteriol       Date:  1998-01

7.  Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant.

Authors:  S L Reckseidler; D DeShazer; P A Sokol; D E Woods
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

8.  Laboratory-acquired human glanders--Maryland, May 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-06-23       Impact factor: 17.586

9.  The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence.

Authors:  D DeShazer; P J Brett; D E Woods
Journal:  Mol Microbiol       Date:  1998-12       Impact factor: 3.501

Review 10.  Adjuvants for human vaccines--current status, problems and future prospects.

Authors:  R K Gupta; G R Siber
Journal:  Vaccine       Date:  1995-10       Impact factor: 3.641

View more
  22 in total

1.  Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.

Authors:  Christopher L Hatcher; Tiffany M Mott; Laura A Muruato; Elena Sbrana; Alfredo G Torres
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

2.  Efficacy of postexposure therapy against glanders in mice.

Authors:  David M Waag
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  The type IV pilin of Burkholderia mallei is highly immunogenic but fails to protect against lethal aerosol challenge in a murine model.

Authors:  Paula J Fernandes; Qin Guo; David M Waag; Michael S Donnenberg
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

Review 4.  Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.

Authors:  Sara K Bondi; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

5.  Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.

Authors:  Sylvia R Treviño; Amy R Permenter; Marilyn J England; Narayanan Parthasarathy; Paul H Gibbs; David M Waag; Tran C Chanh
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

Review 6.  The role of nuclear technologies in the diagnosis and control of livestock diseases--a review.

Authors:  Gerrit J Viljoen; Antony G Luckins
Journal:  Trop Anim Health Prod       Date:  2012-10       Impact factor: 1.559

7.  Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders.

Authors:  Mary N Burtnick; Christian Heiss; Rosemary A Roberts; Herbert P Schweizer; Parastoo Azadi; Paul J Brett
Journal:  Front Cell Infect Microbiol       Date:  2012-08-15       Impact factor: 5.293

Review 8.  Burkholderia vaccines: are we moving forward?

Authors:  Leang-Chung Choh; Guang-Han Ong; Kumutha M Vellasamy; Kaveena Kalaiselvam; Wen-Tyng Kang; Anis R Al-Maleki; Vanitha Mariappan; Jamuna Vadivelu
Journal:  Front Cell Infect Microbiol       Date:  2013-02-05       Impact factor: 5.293

Review 9.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

10.  Development of novel O-polysaccharide based glycoconjugates for immunization against glanders.

Authors:  Mary N Burtnick; Christian Heiss; A Michele Schuler; Parastoo Azadi; Paul J Brett
Journal:  Front Cell Infect Microbiol       Date:  2012-11-27       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.